Dutoprol News

BOX WARNING

Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered DUTOPROL, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1–2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, DUTOPROL or beta-blocking agent administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue DUTOPROL therapy abruptly even in patients treated only for hypertension.

NEWS HIGHLIGHTS

Media Articles Related to Dutoprol (Metoprolol / Hydrochlorothiazide)

'MAP' Program Improves Hypertension Control Source: theheart.org | Medscape Cardiology Headlines [2017.09.19]The MAP program focuses on an accurate BP, intensifying treatment when an elevated BP is confirmed, and partnering with the patient to select and carry out the treatment plan. Medscape Medical News

Hypertension Control Varies by Geography, DemographicsSource: Medscape Nephrology Headlines [2017.09.19]According to a new study of hypertensive US adults, two thirds of patients have their condition under control, and wide geographic and demographic differences in hypertension control exist. Medscape Medical News